These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18340241)

  • 1. Exemestane: an alternative treatment option in early breast cancer. Foreward.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S1. PubMed ID: 18340241
    [No Abstract]   [Full Text] [Related]  

  • 2. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
    Goss PE; Richardson H; Chlebowski R; Johnston D; Sarto GE; Maunsell E; Ingle JN; Alés-Martinez JE
    Clin Breast Cancer; 2007 Dec; 7(11):895-900. PubMed ID: 18269782
    [No Abstract]   [Full Text] [Related]  

  • 3. The evolving role of exemestane in the management of breast cancer.
    Bundred N
    Br J Hosp Med (Lond); 2006 Aug; 67(8):427-30. PubMed ID: 16918105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 5. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 6. Exemestane: a milestone against breast cancer.
    Shetty YC; Chakkarwar PN; Acharya SS; Rajadhyaksha VD
    J Postgrad Med; 2007; 53(2):135-8. PubMed ID: 17495383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intergroup Exemestane Study mature analysis: overall survival data.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis in cancer clinical trials.
    Jeong JH
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S9-10. PubMed ID: 18340243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 10. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 11. Exemestane for advanced breast cancer.
    Med Lett Drugs Ther; 2000 Apr; 42(1076):35-6. PubMed ID: 10803175
    [No Abstract]   [Full Text] [Related]  

  • 12. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
    Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
    Chin YS; Beresford MJ; Ravichandran D; Makris A
    Breast; 2007 Aug; 16(4):436-9. PubMed ID: 17418575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane for breast-cancer prevention.
    Hanaoka M; Takano T; Kawabata H
    N Engl J Med; 2011 Sep; 365(11):1056-7; author reply 1057-8. PubMed ID: 21916645
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
    Wang LP; Shen KW; Shan ZZ
    Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):764-6. PubMed ID: 16483497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.